Orthocell Limited (ASX:OCC), a regenerative medicine company, has disclosed its participation in the Canaccord Genuity 46th Annual Growth Conference, being held in Boston from 11 to 13 August 2026, with Chairman John Van Der Wielen and Managing Director Paul Anderson attending to meet with life sciences investors.
Key Points
- Orthocell is participating in the Canaccord Genuity 46th Annual Growth Conference in Boston, 11–13 August 2026
- Chairman John Van Der Wielen and Managing Director Paul Anderson will meet with life sciences investors at the conference
- An investor presentation has been attached to the company's filing
- The company disclosed $44 million in cash reserves, no financial debt and no royalty liabilities
Conference Participation Details
Orthocell disclosed its attendance at the Canaccord Genuity 46th Annual Growth Conference, scheduled to run from 11 to 13 August 2026 in Boston. The filing states that investors attending the conference may request a one-on-one meeting with Orthocell through their Canaccord Genuity sales representative. The release was authorised by Paul Anderson, Orthocell's Chief Executive Officer and Managing Director. An investor presentation prepared for the conference was attached to the company's filing.
Remplir Commercial Update and Global Clearances
According to the investor presentation included in the filing, Orthocell's Remplir product for peripheral nerve reconstruction is approved and selling in Australia, New Zealand, the United States, Canada, Singapore, Hong Kong and Thailand. The filing states that EU and UK clearance is expected in the second half of calendar year 2026. The company's investor presentation also states that Remplir US key commercial metrics are demonstrating strong growth with sales continuing to build, and that the company is anticipating a material uplift in US revenue in the upcoming quarters.
Financial Position and Product Portfolio
The investor presentation discloses that Orthocell holds $44 million in cash reserves, carries no financial debt and has no royalty liabilities. The company describes itself as an Australian medical technology company with growing international revenue. Its product portfolio includes collagen medical devices for dental and orthopaedic reconstructive applications, with Striate+™ cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil, and distributed globally by BioHorizons Implant Systems Inc. The filing also references the global nerve repair market as US$3.5 billion.





Please wait processing your request...